Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

    NEXT STORY
    Beroni Group Announces Webcast from Biotech Showcase™ 2020 in San Francisco, USA
    PREV STORY
    Colorectal Cancer Therapeutics Market to reach USD 16.58 billion by 2026, Presence of Strong Oncology Portfolio to help Players Gain Competitive: Reports Fortune Business Insights™
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Merus annonce l’acceptation de six résumés lors des prochains congrès médicaux et fournit des mises à jour du programme

    author_avatar
    NASDAQ Market News

    Worldwide Licorice Industry to 2025 – by Form, Application and Geography

    author_avatar
    NASDAQ Market News

    Mateon Announces Issuance of US Patent for Cathepsin Inhibition

    SOUTH SAN FRANCISCO, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), ...

    author_avatar
    NASDAQ Market News